Galecto Set to Join Russell Microcap® Index
BOSTON, June 20, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel…
Browsing Tag
Galecto
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
<!-- Name:DistributionId Value:8780653 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Galecto Announces Upcoming Poster Presentation Detailing Results from the…
Intermediate assessment of GB2064 in the Phase 2 myelofibrosis trial showed target engagement in the bone marrow and reduction in collagen fibrosis in four out of five evaluable patients…
Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant…
Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseasesFindings to be discussed in a conference call and virtual…
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis,…
BOSTON, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer,…
Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall…
BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer,…
Galecto’s GB0139 Shows Favorable Safety and Tolerability Profile with Promising…
GB0139 significantly reduced oxygen flow requirements and improved several biomarkers for lung and systemic inflammation, liver function, tissue damage and coagulationData demonstrate…